tbuckley/cabot-search huggingface dataset:
Recent Advances in Physiology.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Electronic patient reporting outcomes are a promising predictive factor of prostate cancer patient survival: The Protecty study.
Authors: Carole Helissey, Clémentine Riviere, Selma Becheriat, Hélène Vanquaethem, Charles Parnot, Laurent Brureau
Journal: Journal of Clinical Oncology (2022)

76 Background: The benefits of Electronic Patient Remote Outcomes (e-PRO) for telemonitoring are well established, allowing early detection of illnesses and continuous monitoring of patients. We have previously shown high levels of compliance of use of telemonitoring in daily care. This new PROTECTY study assesses the predictive power of patient health status in the first month of treatment on survival, evaluated with the telemonitoring platform Cureety. Methods: This prospective study was conducted at the Military Hospital Bégin on prostate cancer patients. Patients were allowed to respond to a symptomatology questionnaire based on CTCAE v.5.0, personalized to their pathology and treatment. An algorithm evaluates the health status of the patient based on the reported adverse events, with a classification into 2 different states: Good Health status (A) Poor Health status (B) In case of A, the patient received therapeutic advice to help manage each of the reported adverse events. In case of B, the patient is invited to call the hospital. For the purpose of this analysis, we collected their health status during the first month after initiation of treatment. The primary endpoint was to assess if the first month health status is a predictive factor of progression free-survival (PFS) for prostate cancer patient. The secondary endpoint was to assess if the first month health status is a predictive factor of overall survival (OS) for prostate cancer patient. Results: Sixty-one patients were enrolled between July 1st, 2020 and June 30 st , 2021. The median age was 74.0 (range 58.0 – 94.0). 62% presented a metastatic stage, and the most represented cancer was mHSPC with 39,5% among metastatic patients. Overall, 2443 questionnaires were completed by the patients, 4.0% resulted in a health classification in state B. 86,9% of patient were classified in group A the first month. 13,1% of patient were classified in group B the first month. The median follow up was 12.3 months. PFS at 12 months was 89% in A group vs 60% in B group, p=0,17 OS at 12 months was 100% in A group vs 86% in B group, p=0,15. Conclusions: Our study is the first to assess the impact of tolerance treatment on survival. The initial results suggest that e-PRO assessment by the platform could help identify in the early stages the patients that require further health assessment and potential therapeutic changes. While further follow-up of more patients will be required, our study highlights the importance of e-PRO in cancer patient care.
The Heberden Society
Journal: Annals of the Rheumatic Diseases (1948)

In a short communication read before the Heber- den Society recently, Mr. W. D. Coltart described the condition of degenerative patello-femoral arthritis.Degenerative changes in the patellar articular cartilage are common post-mortem and operative findings, and well marked patello-femoral crepitus is often observed in symptomless knees Occasionally the condition becomes painful, and disabling and cases can be divided into three clinica groups: (1) arthritis of the patello-femoral articula tion occurring after a fracture of the patella; (2 a post-traumatic condition without definite fracture (3) cases of apparently spontaneous origin.The affection can be recognized by a definite syndrome of: (a) characteristic pain in the-patella area, (b) patellar tenderness, (c) pain referred to the patello-femoral region on active extension of the knee against resistance, (d) complete relief of painfu symptoms when the knee is immobilized in plastei and the immediate recurrence of these symptom4 when the plaster is removed, (e) a rather remarkablc absence of sign of generalized arthritis of the knee and no radiographic changes.Conservative treatment is unsuccessful in th majority ofcases, and patellectomy is often indicated At operation the articular cartilage of the patellar ir seen to be fibrillated, tufted, and discoloured Later there is erosion of the cartilage and eburnatior of the underlying bone.Although degenerative patello-femoral arthritis ir its turn may give rise to a true osteo-arthritis of the knee, it should at first be regarded as a clinica entity and not simply as part of a generalizec affection of the whole joint.
Author Index
Authors: Ilkka T. Harvima, Heimo Viinamäki, Anita Naukkarinen, Kari Paukkonen, Heikki Neittaanmäki, Rauno J. Harvima, Maija Horsmanheimo, Denise M. Tope, Tim A. Ahles, Peter M. Silberfarb, Andrew B. Littman, M.G. Madianos, D. Madianou-Gefou, C.N. Stefanis, Michael W. Otto, Ronald A. Yeo, Brüt-Maj Wikström, Töres Theorell, Sven Sandström, Graeme J. Taylor, K.M. Bagby, J.D.A. Parker, Paul C. Horton, Herbert Gewirtz, Karole J. Kreutter, P. Bech, Jean Cottraux, Michael Bach, Doris Bach
Journal: Psychotherapy and Psychosomatics (1993)
SIDS: Is It Increasing?
Authors: Leonard T. Kurland
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The recent article by Khoury et al<sup>1</sup>provides death certificate data that show a dramatic increase in the reported rates of sudden infant death syndrome (SIDS) for both blacks and whites, beginning in the 1960s. The authors postulate that all or part of this reported increase may be due to changes in the<i>International Classification of Diseases, Adapted</i>coding schema and/or artifacts of registration. Two population-based studies of SIDS have been conducted by investigators at the Mayo Clinic, Rochester, Minn (R.C.N., unpublished data, January 1966 to December 1981 ).<sup>2</sup>In both studies, for all cases of infant neonatal and postneonatal mortality, death certificates were linked to medical records and autopsy protocols (the overall autopsy rate was 83%). Case ascertainment was complete and diagnoses were verified by exclusion. The annual incidence rate of SIDS for Olmsted County, Minnesota, for the time frame 1946 to 1965 was 1.2
NEWBORN ORGAN ABNORMALITIES AND MATERNAL GLUCOSE METABOLISM
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study
Authors: Clive Kearon, Kerstin de Wit, Sameer Parpia, Sam Schulman, Frederick A Spencer, Sangita Sharma, Marc Afilalo, Susan R Kahn, Gregoire Le Gal, Sudeep Shivakumar, Shannon M Bates, Cynthia Wu, Alejandro Lazo-Langner, Frédérick D'Aragon, Jean-François Deshaies, Luciana Spadafora, Jim A Julian
Journal: BMJ (2022)

Abstract Objective To evaluate the safety and efficiency of a diagnostic algorithm for deep vein thrombosis (DVT) that uses clinical pretest probability based D-dimer thresholds to exclude DVT. Design Prospective diagnostic management study. Setting University based emergency departments or outpatient clinics in Canada. Participants Patients with symptoms or signs of DVT. Intervention DVT was considered excluded without further testing by Wells low clinical pretest probability and D-dimer &lt;1000 ng/mL or Wells moderate clinical pretest probability and D-dimer &lt;500 ng/mL. All other patients had proximal ultrasound imaging. Repeat proximal ultrasonography was restricted to patients with initially negative ultrasonography, low or moderate clinical pretest probability, and D-dimer &gt;3000 ng/mL or high clinical pretest probability and D-dimer &gt;1500 ng/mL. If DVT was not diagnosed, patients did not receive anticoagulant treatment. Main outcome measure Symptomatic venous thromboembolism at three months. Results 1508 patients were enrolled and analysed, of whom 173 (11.5%) had DVT on scheduled diagnostic testing. Of the 1275 patients with no proximal DVT on scheduled testing who did not receive anticoagulant treatment, eight (0.6%, 95% confidence interval 0.3% to 1.2%) were found to have venous thromboembolism during follow-up. Compared with a traditional DVT testing strategy, this diagnostic approach reduced the need for ultrasonography from a mean of 1.36 scans/patient to 0.72 scans/patient (difference −0.64, 95% confidence interval −0.68 to −0.60), corresponding to a relative reduction of 47%. Conclusions The diagnostic strategy using a combination of clinical pretest probability and D-dimer identified a group of patients at low risk for DVT during follow-up while substantially reducing the need for ultrasound imaging. Registration ClinicalTrials.gov NCT02038530 .
Comparison of patients with high-risk nonmetastatic clear cell renal carcinoma in adjuvant therapy trials versus nonclinical trial patients.
Authors: Jen Hoogenes, Rodney H. Breau, Bimal Bhindi, Ricardo A. Rendon, Simon Tanguay, Antonio Finelli, Alan So, Luke Lavallee, Frederic Pouliot, Jean-Baptiste Lattouf, Lucas W. Dean, Darrel E Drachenberg, Lori Wood, Naveen S. Basappa, Daniel Yick Chin Heng, Aaron Richard Hansen, Denis Soulieres, Georg A. Bjarnason, Ranjeeta Mallick, Anil Kapoor
Journal: Journal of Clinical Oncology (2022)

361 Background: Characteristics of patients with high risk for recurrence non-metastatic renal cell carcinoma (nmRCC) participating in adjuvant therapy clinical trials post-nephrectomy have not been well described. We evaluated high risk nmRCC patients in the CKCis database to explore differences between trial and non-trial patients. Methods: Adult patients undergoing partial or radical nephrectomy for clear cell nmRCC between January 1, 2011 and March 31, 2021 were included. CKCis is a prospective cohort of patients from 14 Canadian academic institutions. Patients with high risk nmRCC (using modified UCLA Integrated Staging System) were included. Demographic, clinical, and survival statistics were analyzed for all patients and comparatively for the trial and non-trial groups. Results: 1459 patients, including 63 in adjuvant trials, were evaluated. 71% were male, 91% had pT3N0M0 disease. Disease characteristics including tumor size, stage, grade, location, necrosis, and margin status were similar between groups. Trial patients were younger (mean age 58.1 vs. 63.6; p &lt; 0.0001) and had lower Charlson Comorbidity Index scores (median 4 [3,6) vs. 5 [4,6] p &lt; 0.001). Estimated overall survival (OS) at 5 years was 80.8% (95% CI, 65,90) for trial patients and 74.8% (95% CI, 71,78.2) for non-trial patients. Recurrence-free survival at 5 years for trial patients was 48.6% (95% CI, 34,61.7) and 39.2% (95% CI, 35.2,43.1) for non-trial patients. Conclusions: Patients in adjuvant trials were younger and healthier at baseline than the average high risk nmRCC CKCis patient. Trial patients appear to have had longer time to recurrence and longer survival compared to non-trial patients, although not reaching statistical significance. Selection bias is common in clinical trials and evaluation of real-world population-based evidence of patients receiving adjuvant therapy will be important to ensure phase 3 trial results have external validity.
Book Review Arthritis in Modern Practice: The diagnosis and management of rheumatic and allied conditions . By Otto Steinbrocker, M.D. With chapters on painful feet, posture and exercises, splints and supports, manipulative treatment, and operations and surgical procedures by John G. Kuhns, M.D. 8°, cloth, 606 pp., with 321 illustrations. Philadelphia: W. B. Saunders Company, 1941. $8.00.
Journal: New England Journal of Medicine (1942)
BRACHIAL NEURALGIA
Authors: R. M. Simon
Journal: BMJ (1903)

BRAGHIAATJITUGBI [lJOT t' *71[After the present paper liad been written the record of a very interesting successfu lcase, by Dr. E. C. Taylor, appeare%I in the Lancet for June 6th, I903.]What has' been s,aid will serve to point 1th e moPaL that unrelaxed vigilance must be observed in every case, and during every stage, of a radical-cure-of herniia, w he her inguinal or femoral,, the bladder, as,already stated, being occasionally'found in the sac of a femo6alheriua.
Cervical cytology.
Authors: T. K. Maurice
Journal: BMJ (1968)

DBIAL Jo same.When it came to weight changes, I found that all but one of the 12 patients lost weight while receiving Sintisone (2-12 lb.(1-5 kg.) in 28 days) and one patient gained 2 lb.(1 kg.) in 28 days while receiving Sintisone.A fact which emerged at the end of the evaluation was that the maintenance dose of Sintisone calculated as prednisolone was lower than that of prednisolone.On the basis of these findings there would appear to be at least two advantages in using Sintisone: one the lesser water retention, and the other lower maintenance dose.I feel that if these findings can be confirmed Sintisone may prove to be particularly useful in the long-term management of many conditions, not least the asthmatic patient.-Iam, etc.,
Phenylketonuria.
Authors: B E Clayton, O H Wolff
Journal: BMJ (1970)

Lung Biopsy SIR,-Your leading article on lung biopsy (6 June, p. 555) cannot be allowed to pass without comment.To say that "owing to the indifferent contribution it has made in assisting diagnosis over the years the method has now been virtually abandoned" suggests that your leader writer cannot be familiar with either the paper by Steel and Winstanley' or with current practice in a number of hospitals all over the world.Quite contrary to the view quoted above, I believe that trephine biopsy has made a great contribution to the diagnosis of diffuse lung disease, and the procedure has converted me from being a keen advocate of open lung biopsy to an ardent supporter of the much simpler technique.To suggest that the procedure is more alarming or more liable to morbidity than a formal thoracotomy under general anaesthesia in an operating theatre seems to me to be pushing the objection of trephine biopsy beyond the limits of reason.-Iam, etc.,
Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).
Authors: Christopher J. Hoimes, Thomas W. Flaig, Sandy Srinivas, Nataliya Mar, Daniel P. Petrylak, Peter H. O'Donnell, Mehmet Asim Bilen, Carolyn Sasse, Yao Yu, Matthew Birrenkott, Jonathan E. Rosenberg
Journal: Journal of Clinical Oncology (2022)

TPS587 Background: The current standard of care for patients (pts) with newly diagnosed MIBC is neoadjuvant cisplatin (cis)-based chemotherapy followed by radical cystectomy and pelvic lymph node dissection (RC+PLND). For the 20-50% pts who are cis-ineligible, the current standard of care is RC+PLND alone (Galsky Future Oncol 2021). Adjuvant therapy is currently recommended for cis-ineligible patients with high-risk features at cystectomy. Due to the high rates of recurrence in cis-ineligible pts with RC+PLND alone, there is a need to develop new therapies in this setting. Enfortumab vedotin (EV), an antibody-drug conjugate, delivers the microtubule-disrupting agent monomethyl auristatin E to cells expressing Nectin-4, which is highly expressed in urothelial cancer. In EV-301, a phase 3 study, EV showed an overall survival (OS) benefit vs chemotherapy in pts with locally advanced (la) or metastatic urothelial carcinoma (mUC) who had previously received platinum-based therapy and a PD-1 or PD-L1 inhibitor (Powles NEJM 2021). EV has also demonstrated activity and a tolerable safety profile in cis-ineligible pts with la/mUC (Yu Lancet Oncol 2021). Given the efficacy of EV in la/mUC, it is being evaluated as perioperative therapy in cis-ineligible MIBC in EV-103 cohort L. Methods: Study EV-103 (NCT03288545) la/mUC and MIBC cohorts were described previously (Hoimes ASCO 2019; Hoimes ASCO-GU 2020). Cohort L was added to evaluate EV monotherapy (n = 50) as perioperative therapy in cis-ineligible pts with MIBC (cT2-T4aN0M0 or cT1-T4aN1M0). Eligible pts are previously untreated for MIBC, ECOG 0-2, have CrCl ≥30 mL/min, and are medically fit for and agree to undergo curative intent RC+PLND. Pts with pT1 disease are eligible only if they have N1 disease. Pts receive 3 cycles of neoadjuvant EV (1.25 mg/kg IV) on Days 1 and 8 of each 3-week cycle, followed by RC+PLND and then 6 cycles of adjuvant EV starting 8 weeks post-RC on the same schedule. Pathological complete response rate per central pathology review is the primary endpoint. Secondary endpoints include event-free survival and disease-free survival by blinded independent central review and investigator, pathological downstaging rate per central pathology review, OS, safety and tolerability. Cohort L is currently enrolling pts in the US and Canada. Clinical trial information: NCT03288545.
Correlation of the rate of metastasis-free survival with the presence of pathogenic germline genetic mutations in patients with prostate cancer at a community practice.
Authors: Siddharth Ramanathan, Sadhna Ramanathan, Alvaro Martinez, Andrew Korman, Michael Ghilezan, Michael Levin, Zachary Alan Gerndt, Nathan Shen, Kirk Wojno, Howard Korman, Savitha Balaraman
Journal: Journal of Clinical Oncology (2022)

70 Background: Loeb et al. recently highlighted that academic physicians were statistically more likely to recommend genetic testing to prostate cancer patients per NCCN guidelines compared to physicians at community practices. Several articles have outlined the rate of pathogenic mutations and metastasis free survival (MFS) for prostate cancer patients treated at academic institutions. However, there is a relative paucity of equivalent data regarding patients treated at community urology clinics. We felt it was important to retrospectively review data from our large community based uro-oncology practice and present our findings in an effort to clarify this topic. Methods: We collected data on 562 prostate cancer patients treated at our multidisciplinary uro-oncology clinic between 2016 and 2018. We found 363 patients that satisfied the inclusion criteria of having germline genetic mutation testing and at least 1 year of follow-up. Patients were stratified into three categories based on the results of their germline genetic test: negative for germline mutations, positive for germline pathogenic mutations, or positive for VUS (variant of uncertain significance) mutations. Analysis of variances (ANOVA) was conducted to assess for any differences in age, Gleason score, metastasis rate, and MFS across the groups. A significance level of.05 was used. Results: All patients were treated according to guideline recommendations as was standard for the practice. There was no statistically significant difference in average age or Gleason score between the groups. There was also no statistically significant difference between the MFS across the three groups. Although the metastasis rate and MFS in the group without any mutations (9.8%, 18.3 months) was clinically significant compared to the groups with pathogenic mutations (7.5%, 16.5 months) and VUS mutations (7%, 16.6 months), the differences were not statistically significant (p=.754 and.127 respectively). Conclusions: In our community based uro-oncology practice, we found no statistically significant difference in MFS between patients with pathogenic germline mutations, patients without germline mutations, and patients with VUS mutations at 1 year of follow-up. This does not exclude the possibility of an impact of germline mutations on MFS as the data matures to reach 5 or more years of follow-up.[Table: see text]
THE UTILITY OF ALCOHOL AS A DISINFECTANT.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Autoimmune Diseases
Authors: John J. Condemi
Journal: JAMA (1992)

SINCE the earliest descriptions of the immune system, the ability of an individual to react to a wide variety of foreign and endogenous antigens, while not responding to one's own self, has intrigued researchers. The first descriptions of autoimmune phenomena in the early 1900s aroused sufficient anxiety to cause Ehrlich to coin the term "horror autotoxicus" to describe the situation in which an individual would attempt to destroy himself or herself. This horror at physiological self-destructive mechanisms was certainly justified with the delineation of the many autoimmune disease states. What has changed since then, however, is the recognition that the production of autoimmunity is a common phenomenon, often under normal immune regulation, and that in some situations, such as the response to cancer cells, it may benefit the individual. There has also been speculation that autoantibodies are the markers by which the phagocytic system recognizes and removes old red blood